Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Compare

11,611 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Hold

4 Buy

14 Hold

1 Sell

Based on 19 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$51.93

▲(14.48% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $51.93 with a high forecast of $65.00 and a low forecast of $34.00. The average price target represents a 14.48% change from the last price of $45.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","66":"$66","41.25":"$41.3","49.5":"$49.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,41.25,49.5,57.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.23,45.8276923076923,47.425384615384615,49.02307692307692,50.62076923076923,52.21846153846154,53.816153846153846,55.41384615384615,57.011538461538464,58.60923076923077,60.206923076923076,61.80461538461539,63.402307692307694,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.23,44.82230769230769,45.41461538461538,46.00692307692307,46.599230769230765,47.19153846153846,47.783846153846156,48.37615384615384,48.96846153846154,49.56076923076923,50.153076923076924,50.745384615384616,51.33769230769231,{"y":51.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.23,43.44307692307692,42.65615384615384,41.86923076923077,41.08230769230769,40.29538461538461,39.50846153846154,38.72153846153846,37.934615384615384,37.14769230769231,36.36076923076923,35.573846153846155,34.786923076923074,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.7,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.52,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":52.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$51.93

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$47

Hold

3.62%

Upside

Reiterated

08/01/25

Bristol-Myers Squibb's overall stock score of 67 reflects strong financial performance and positive earnings call sentiment, offset by bearish technical indicators and some valuation concerns. The company's ability to manage liabilities and stabilize earnings will be crucial for future performance.

Narumi NakagiriDaiwa

Daiwa

$42

Hold

-7.41%

Downside

Downgraded

08/05/25

Bristol Myers downgraded to Neutral from Outperform at DaiwaBristol Myers downgraded to Neutral from Outperform at Daiwa

David RisingerLeerink Partners

Leerink Partners

$55→$53

Buy

16.84%

Upside

Reiterated

08/04/25

Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Drug Pipeline and Strategic Reviews

Evan SeigermanBMO Capital

BMO Capital

$47

Hold

3.62%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN), Galapagos (NASDAQ: GLPG) and Bristol-Myers Squibb (NYSE: BMY)

Trung HuynhUBS

UBS

$52→$46

Hold

1.41%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $46 from $52 at UBSBristol Myers price target lowered to $46 from $52 at UBS

Tim AndersonBank of America Securities

Bank of America Securities

$56→$50

Hold

10.23%

Upside

Reiterated

08/01/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges

Geoff MeachamCiti

Citi

$51→$47

Hold

3.62%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $47 from $51 at CitiBristol Myers price target lowered to $47 from $51 at Citi

Chris SchottJ.P. Morgan

J.P. Morgan

$67→$65

Buy

43.30%

Upside

Reiterated

08/01/25

Bristol-Myers Squibb (BMY) Receives a Buy from J.P. MorganJPMorgan analyst Chris Schott lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $65.00 (from $67.00) while maintaining a Overweight rating.

Courtney BreenBernstein

Bernstein

$58

Hold

27.87%

Upside

Reiterated

08/01/25

Balanced Outlook on Bristol-Myers Squibb: Strong Earnings Amid Strategic UncertaintiesWe lower our price target to $58 ($62 prev.) on account of a slower Cobenfy launch & more uncertainty on the future expansions and see the ADEPT2 trial as a key catalyst. Investment Implications We rate BMY Market-Perform with a price target of $58 2025 BMY Close Price (USD) 43.31 Price Target (USD) 58.00 63.33/42.96 SPX 6,339.39 FYE Cap (USD) (M) 88,155 EV (USD) (M) 123,391 Performance YTD 1M 6M 12M Absolute (%) (23.4) (8.8) (26.5) (10.1) SPX (%) 7.8 2.2 4.9 14.8 Relative (%) (31.2) (11.0) (31.5) (24.9) Source: Bloomberg, Bernstein estimates and analysis.

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

08/01/25

Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/01/25

Guggenheim Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Steve ScalaTD Cowen

TD Cowen

$54

Hold

19.05%

Upside

Reiterated

07/31/25

Bristol-Myers Squibb (BMY) Receives a Hold from TD Cowen

Terence FlynnMorgan Stanley

Morgan Stanley

$34

Sell

-25.04%

Downside

Reiterated

07/31/25

Sell Rating for Bristol-Myers Squibb Due to Overly Optimistic Estimates and Clinical Trial DelaysWe see risk to 2026+ estimates. BMY shares traded down -5.7% on 7/31 (vs. S&P500 -0.4%) likely driven by questions around the quality of the 2Q beat (see our first take HERE and more below) and BMY's commentary on the earnings call noting that they are conducting clinical trial site reviews, which could impact data timelines for the Ph3 trial. For context the company’s prior guidance for data timing was late 3Q/ early 4Q, but mgmt noted that the data are still expected by YE25. We followed up with IR who indicated that the company elected to take a look across all of their ongoing clinical trials in light of recent trial failures (Camzyos ODYSSEY-HCM, Cobenfy ARISE and Reblozyl INDEPENDENCE) to ensure that probability of success for future trials is as high as possible, and this is not solely focused on ADEPT-2.

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

07/31/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Results and Conservative Guidance

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$55

Hold

21.25%

Upside

Reiterated

07/29/25

Bristol-Myers Squibb (BMY) Gets a Hold from Cantor FitzgeraldCantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $55.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$47

Hold

3.62%

Upside

Reiterated

08/01/25

Narumi NakagiriDaiwa

Daiwa

$42

Hold

-7.41%

Downside

Downgraded

08/05/25

Bristol Myers downgraded to Neutral from Outperform at DaiwaBristol Myers downgraded to Neutral from Outperform at Daiwa

David RisingerLeerink Partners

Leerink Partners

$55→$53

Buy

16.84%

Upside

Reiterated

08/04/25

Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Drug Pipeline and Strategic Reviews

Evan SeigermanBMO Capital

BMO Capital

$47

Hold

3.62%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Stevanato Group (NYSE: STVN), Galapagos (NASDAQ: GLPG) and Bristol-Myers Squibb (NYSE: BMY)

Trung HuynhUBS

UBS

$52→$46

Hold

1.41%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $46 from $52 at UBSBristol Myers price target lowered to $46 from $52 at UBS

Tim AndersonBank of America Securities

Bank of America Securities

$56→$50

Hold

10.23%

Upside

Reiterated

08/01/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges

Geoff MeachamCiti

Citi

$51→$47

Hold

3.62%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $47 from $51 at CitiBristol Myers price target lowered to $47 from $51 at Citi

Chris SchottJ.P. Morgan

J.P. Morgan

$67→$65

Buy

43.30%

Upside

Reiterated

08/01/25

Courtney BreenBernstein

Bernstein

$58

Hold

27.87%

Upside

Reiterated

08/01/25

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

08/01/25

Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/01/25

Guggenheim Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Steve ScalaTD Cowen

TD Cowen

$54

Hold

19.05%

Upside

Reiterated

07/31/25

Bristol-Myers Squibb (BMY) Receives a Hold from TD Cowen

Terence FlynnMorgan Stanley

Morgan Stanley

$34

Sell

-25.04%

Downside

Reiterated

07/31/25

Matt PhippsWilliam Blair

William Blair

―

Hold

―

Reiterated

07/31/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Results and Conservative Guidance

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

$55

Hold

21.25%

Upside

Reiterated

07/29/25

Bristol-Myers Squibb (BMY) Gets a Hold from Cantor FitzgeraldCantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $55.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

1 Month

xxx

Success Rate

11/24 ratings generated profit

Average Return

+0.60%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.83% of your transactions generating a profit, with an average return of +0.60% per trade.

3 Months

xxx

Success Rate

15/24 ratings generated profit

Average Return

+2.52%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.52% per trade.

1 Year

Terence FlynnMorgan Stanley

Success Rate

20/24 ratings generated profit

Average Return

+9.98%

reiterated a sell rating 9 days ago

Copying Terence Flynn's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +9.98% per trade.

2 Years

xxx

Success Rate

21/24 ratings generated profit

Average Return

+14.97%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +14.97% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 18 Buy Ratings, 40 Hold Ratings, and 3 Sell Ratings. BMY average Analyst price target in the past 3 months is 51.93.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.69 with a range of $1.55 to $1.81. The previous quarter’s EPS was $1.46. BMY beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 35.24% of the time in the same period. In the last calendar year BMY has Outperformed its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $11.75B with a range of $11.48B to $12.06B. The previous quarter’s sales results were $12.27B. BMY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 49.77% of the time in the same period. In the last calendar year BMY has Outperformed its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 51.93.

What is BMY’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb has 14.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMY a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Hold which is based on 4 buy ratings, 14 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s price target?

The average price target for Bristol-Myers Squibb is 51.93. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $34.00. The average price target represents 14.48% Increase from the current price of $45.36.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of BMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts